Literature DB >> 15365015

Accurate representation of the hepatitis C virus quasispecies in 5.2-kilobase amplicons.

Zhi Liu1, Dale M Netski, Qing Mao, Oliver Laeyendecker, John R Ticehurst, Xiao-Hong Wang, David L Thomas, Stuart C Ray.   

Abstract

Hepatitis C virus (HCV) exists as a swarm of genetically distinct but related variants, or a quasispecies, whose complexity and sequence evolution are critical to studies of viral pathogenesis. Because most studies of the HCV quasispecies have focused on a relatively small genomic segment, the first hypervariable region of the E2 gene, it is possible that viral complexity is occasionally underestimated (due to primer mismatch) and that sequence evolution is misperceived due to unrecognized covariation. This report describes a sensitive and reproducible method to amplify most of the HCV genome as a single 5.2-kb amplicon by using primers directed at relatively conserved genomic segments. Using 52 specimens obtained during acute infection over a range of viral RNA concentrations, the overall rate of successful amplification was 94% and varied in a concentration-dependent manner, with successful amplification in 26 of 26 (100%) specimens at greater than 10(5) IU/ml, 15 of 16 (94%) at 10(4) to 10(5) IU/ml, 6 of 7 (86%) at 10(3) to 10(4) IU/ml, and 2 of 3 (67%) at less than 10(3) IU/ml. Quasispecies complexity, determined by using this novel long-amplicon method followed by heteroduplex mobility assay combined with single-stranded conformational polymorphism (HDA+SSCP) analysis, was very high, even during acute HCV infection, when 10 to 21 (median, 16) different HDA+SSCP patterns were detected among 33 cDNA clones examined. Replicate analyses indicate that this diversity is not dominated by random errors generated during amplification. Therefore, the HCV quasispecies is highly complex even during acute infection and is accurately represented in amplicons representing more than half of the viral genome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15365015      PMCID: PMC516368          DOI: 10.1128/JCM.42.9.4223-4229.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  34 in total

1.  A highly efficient method for long-chain cDNA synthesis using trehalose and betaine.

Authors:  Andrej-Nikolai Spiess; Richard Ivell
Journal:  Anal Biochem       Date:  2002-02-15       Impact factor: 3.365

2.  Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees.

Authors:  S C Ray; Q Mao; R E Lanford; S Bassett; O Laeyendecker; Y M Wang; D L Thomas
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  Evolutionary trends of the first hypervariable region of the hepatitis C virus E2 protein in individuals with differing liver disease severity.

Authors:  Rebecca Curran; Claire L Jameson; Joanna K Craggs; Anna M Grabowska; Brian J Thomson; Adrian Robins; William L Irving; Jonathan K Ball
Journal:  J Gen Virol       Date:  2002-01       Impact factor: 3.891

4.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

Authors:  M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

5.  High-risk behaviors associated with transition from illicit non-injection to injection drug use among adolescent and young adult drug users: a case-control study.

Authors:  Crystal M Fuller; David Vlahov; Danielle C Ompad; Nina Shah; Amelia Arria; Steffanie A Strathdee
Journal:  Drug Alcohol Depend       Date:  2002-04-01       Impact factor: 4.492

6.  Human immunodeficiency virus seroconversion and evolution of the hepatitis C virus quasispecies.

Authors:  Q Mao; S C Ray; O Laeyendecker; J R Ticehurst; S A Strathdee; D Vlahov; D L Thomas
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

7.  Needlestick transmission of hepatitis C.

Authors:  Mark S Sulkowski; Stuart C Ray; David L Thomas
Journal:  JAMA       Date:  2002-05-08       Impact factor: 56.272

8.  Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation.

Authors:  D J Kittlesen; K A Chianese-Bullock; Z Q Yao; T J Braciale; Y S Hahn
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

9.  Quasispecies heterogeneity and constraints on the evolution of the 5' noncoding region of hepatitis C virus (HCV): relationship with HCV resistance to interferon-alpha therapy.

Authors:  Muriel Soler; Muriel Pellerin; Cécile E Malnou; Daniel Dhumeaux; Katherine M Kean; Jean-Michel Pawlotsky
Journal:  Virology       Date:  2002-06-20       Impact factor: 3.616

10.  A longitudinal analysis of T-cell epitope-coding regions of hepatitis C virus after liver transplantation.

Authors:  Hugo R Rosen; Gail Marousek; Sunwen Chou
Journal:  Transplantation       Date:  2002-07-27       Impact factor: 4.939

View more
  21 in total

1.  Functional characterization of core genes from patients with acute hepatitis C virus infection.

Authors:  Xi Tang; Jessica Wagoner; Amina Negash; Michael Austin; John McLauchlan; Young S Hahn; Hugo R Rosen; Stephen J Polyak
Journal:  J Infect Dis       Date:  2010-03-15       Impact factor: 5.226

2.  Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C.

Authors:  Andrea L Cox; Timothy Mosbruger; Georg M Lauer; Drew Pardoll; David L Thomas; Stuart C Ray
Journal:  Hepatology       Date:  2005-07       Impact factor: 17.425

3.  High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection.

Authors:  Alleluiah Rutebemberwa; Stuart C Ray; Jacquie Astemborski; Jordana Levine; Lin Liu; Kimberly A Dowd; Shalyn Clute; Changyu Wang; Alan Korman; Alessandro Sette; John Sidney; Drew M Pardoll; Andrea L Cox
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

4.  Wide range of quasispecies diversity during primary hepatitis C virus infection.

Authors:  Belinda L Herring; Rose Tsui; Lorraine Peddada; Michael Busch; Eric L Delwart
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion.

Authors:  Sukanya Raghuraman; Heiyoung Park; William O Osburn; Emily Winkelstein; Brian R Edlin; Barbara Rehermann
Journal:  J Infect Dis       Date:  2012-01-31       Impact factor: 5.226

6.  Immunogenicity and cross-reactivity of a representative ancestral sequence in hepatitis C virus infection.

Authors:  Kelly P Burke; Supriya Munshaw; William O Osburn; Jordana Levine; Lin Liu; John Sidney; Alessandro Sette; Stuart C Ray; Andrea L Cox
Journal:  J Immunol       Date:  2012-04-16       Impact factor: 5.422

7.  Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection.

Authors:  Lin Liu; Brian E Fisher; Kimberly A Dowd; Jacquie Astemborski; Andrea L Cox; Stuart C Ray
Journal:  J Virol       Date:  2010-03-03       Impact factor: 5.103

8.  Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution.

Authors:  Lin Liu; Brian E Fisher; David L Thomas; Andrea L Cox; Stuart C Ray
Journal:  Hepatology       Date:  2012-04-18       Impact factor: 17.425

9.  HIV populations are large and accumulate high genetic diversity in a nonlinear fashion.

Authors:  Frank Maldarelli; Mary Kearney; Sarah Palmer; Robert Stephens; JoAnn Mican; Michael A Polis; Richard T Davey; Joseph Kovacs; Wei Shao; Diane Rock-Kress; Julia A Metcalf; Catherine Rehm; Sarah E Greer; Daniel L Lucey; Kristen Danley; Harvey Alter; John W Mellors; John M Coffin
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

10.  Trace amounts of sporadically reappearing HCV RNA can cause infection.

Authors:  Naga Suresh Veerapu; Su-Hyung Park; Damien C Tully; Todd M Allen; Barbara Rehermann
Journal:  J Clin Invest       Date:  2014-07-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.